Phaeohyphomycoses (Brown-Black Moulds)

  • John R. Perfect
  • Barbara D. Alexander
  • Wiley A. Schell


Phaeohyphomycosis, a term first introduced by Ajello and colleagues [1], is an encompassing clinical designation for a spectrum of infections caused by darkly pigmented moulds [2, 3]. In its simplest definition, phaeohyphomycosis is an infection caused by fungi that are characterized by a brown-to-black coloration of their vegetative or spore cell walls. Dark pigmentation of the moulds is caused by deposition within the cell wall of dihydroxynaphthalene melanin that is formed through pentaketide metabolism. These moulds collectively are known as dematiaceous fungi. In most cases the brown coloration of the fungus is apparent in host tissue, but at times it is revealed only when the fungus is grown in culture. The term phaeohyphomycosis (phaeo: dusky or brown; hypho: hyphal) is based on characteristics of the fungi as seen in infected tissue and thus includes many genera and species.


Soft Tissue Infection Brain Abscess Immunosuppressed Patient Solid Organ Transplant Recipient Fungal Keratitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ajello L, Georg LK, Steigbigel RT. A case of phaeohyphomycosis caused by a new species of Phialophora. Mycologia. 1974;66:490–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am. 1988;2:925–38.PubMedGoogle Scholar
  3. 3.
    Rinaldi MG. Phaeohyphomycosis. Dermatol Clin. 1996;14:142–53.Google Scholar
  4. 4.
    de Hoog GS, Guarroe J, Gene J, Figueras MJ. Atlas of Clinical Fungi. 2nd ed. Utrecht: Centaalbureau voor Schimmelcultures; 2000.Google Scholar
  5. 5.
    Schell WA. Dematiaceous Hyphomycetes. In: Howard DH, editor. Fungi Pathogenic for Humans and Animals, revised and expanded. 2nd ed. New York: Marcel Dekker; 2003. p. 565–636.Google Scholar
  6. 6.
    Schell WA, Salkin IF, McGinnis JR. Bipolaris, Exophiala, Scedosporium, Sporothrix and other dematiaceous fungi. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of Clinical Microbiology. 8th ed. Washington: American Society for Microbiology; 2003. p. 1820–47.Google Scholar
  7. 7.
    Ferguson BJ, Barnes L, Bernstein JM, et al. Geographical variation in allergic fungal rhinosinusitis. Otolaryngol Clin North Am. 2000;33:441–9.PubMedCrossRefGoogle Scholar
  8. 8.
    MMWR. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy – United States, July–November, 2002. Morbidity and Mortality Weekly Report MMWR 2002;51:1109–1112.Google Scholar
  9. 9.
    Rao CY, Pachucki C, Cali S, et al. Contaminated product water as the source of Phialemonium curvatum bloodstream infection among patients undergoing hemodialysis. Infect Control Hosp Epidemiol. 2009;30:840–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Welty KE, Perfect JR. Cutaneous mycoses in solid organ transplants. Clin Adv Treat Fungal Infect. 1991;2:1–23.Google Scholar
  11. 11.
    Vukmir RB, Kusne S, Linden P, et al. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient. Clin Infect Dis. 1994;19:714–9.PubMedGoogle Scholar
  12. 12.
    Singh N, Chang FY, Gayowski T, Marino IR. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis. 1997;24:369–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Clancy CJ, Wingard JR, Nguyen MH. Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. Med Mycol. 2000;38:169–75.PubMedGoogle Scholar
  14. 14.
    Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care center. Clin Infect Dis. 2009;48:1033–41.PubMedCrossRefGoogle Scholar
  15. 15.
    del Palacio-Hernanz A, Moore MK, Campbell CK, del Palacio-Perez-Medel A, del Castillo-Cantero R. Infection of the central nervous system by Rhinocladiella atrovirens in a patient with acquired immunodeficiency syndrome. J Med Vet Mycol. 1989;27:127–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Perfect JR, Schell WA, Rinaldi MG. Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. J Med Vet Mycol. 1993;31:175–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Marriott DJ, Wong KH, Aznar E. Scytalidium dimidiatum and Lecythophora hoffmannii: unusual causes of fungal infections in a patient with AIDS. J Clin Microbiol. 1997;35:2949–52.PubMedGoogle Scholar
  18. 18.
    Dixon DM, Polak A, Conner GW. Mel-mutants of Wangiella dermatitidis in mice: evaluation of multiple mouse and fungal strains. J Med Vet Mycol. 1989;27:335–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Dixon DM, Migliozzi J, Cooper Jr CR, Solis O, Breslin B, Szaniszlo PJ. Melanized and non-melanized multicellular form mutants of Wangiella dermatitidis in mice: mortality and histopathology studies. Mycoses. 1992;35:17–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Feng B, Wang X, Hauser M, et al. Molecular cloning and characterization of WdPks1, a gene involved in dihydroxynaphthalene melanin biosynthesis and virulence in Wangiella (Exophiala) dermatitidis. Infect Immun. 2001;69:1781–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Schnitzler N, Peltroche-Llacsahuanga H, Bestier N, Zundorf J, Lutticken R, Haase G. Effect of melanin and carotenoids of Exophiala (Wangiella) dermatitidis on phagocytosis, oxidative burst, and killing by human neutrophils. Infect Immun. 1999;67:94–101.PubMedGoogle Scholar
  22. 22.
    Wang Z, Zheng L, Liu H, Wang Q, Hauser M, Kauffman S, et al. WdChs2p, a class I chitin synthase, together with WdChs3p class III contributes to virulence in Wangiella (Exophiala) dermatitidis. Infect Immun. 2001;69:7517–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Ibrahim-Granet O, de Bievre C, Jendoubi M. Immunochemical characterisation of antigens and growth inhibition of Fonsecaea pedrosoi by species-specific IgG. J Med Microbiol. 1988;26:217–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Fuchs J, Pecher S. Partial suppression of cell mediated immunity in chromoblastomycosis. Mycopathologia. 1992;119:73–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Perfect JR, Schell WA. The newer fungal opportunists are coming. Clin Infect Dis. 1996;22:112–8.Google Scholar
  26. 26.
    Silveira F, Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr Opin Infect Dis. 2001;14:679–84.PubMedGoogle Scholar
  27. 27.
    Benedict LA, Kusne S, Torre-Cisneros J, Hunt SJ. Primary cutaneous fungal infection after solid-organ transplantation. Clin Infect Dis. 1993;15:17–21.Google Scholar
  28. 28.
    Vartian CV, Shlaes DM, Padhye AA, Ajello L. Wangiella dermatitidis endocarditis in an intravenous drug user. Am J Med. 1985;78:703–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Walz R, Bianchin M, Chaves ML, Cerski MR, Severo LC, Londero AT. Cerebral phaeohyphomycosis caused by Cladophialophora bantiana in a Brazilian drug abuser. J Med Vet Mycol. 1997;35:427–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Kaufman SM. Curvularia endocarditis following cardiac surgery. Am J Clin Pathol. 1971;56:466–70.PubMedGoogle Scholar
  31. 31.
    Pauzner R, Goldschmied-Reouven A, Hay I, Vared Z, Ziskind Z, Hassin N, et al. Phaeohyphomycosis following cardiac surgery: case report and review of serious infection due to Bipolaris and Exserohilum species. Clin Infect Dis. 1997;25:921–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis. 2002;34:467–76.PubMedCrossRefGoogle Scholar
  33. 33.
    Kerr C, Perfect JR, Gallis HA, Craven PC, Drutz DJ, Shelburne J, et al. Fungal peritonitis in patients on chronic ambulatory peritoneal dialysis. Ann Intern Med. 1983;99:334–7.PubMedGoogle Scholar
  34. 34.
    Schwartz RA. Superficial fungal infections. Lancet. 2004;364:1173–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Ronan SG, Vzoaru I, Nadimpalli V, Guitart J, Manaligod JR. Primary cutaneous phaeohyphomycosis: report of seven cases. J Cutan Pathol. 1993;20:223–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Forster RK, Rebell G, Wilson LA. Dematiaceous fungal keratitis: clinical isolates and management. Br J Ophthalmol. 1975;59:372–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Schell WA. Oculomycoses caused by dematiaceous fungi. Proceedings of the VI International Conference on the Mycoses. Pan American Health Organization, Washington: Scientific Publication No. 470. 1986, pp105–109.Google Scholar
  38. 38.
    McGinnis MR, Rinaldi MG, Winn RE. Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol. 1986;24:250–9.PubMedGoogle Scholar
  39. 39.
    Thomas RA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16:730–97.PubMedCrossRefGoogle Scholar
  40. 40.
    Wilhemus KR, Jones DB. Curvularia keratitis. Trans Am Ophthalmol Soc. 2001;99:111–30.Google Scholar
  41. 41.
    Sudduth EJ, Crumbley AJ, Farrar WE. Phaeohyphomycosis due to Exophiala species: clinical spectrum of disease in humans. Clin Infect Dis. 1992;15:639–44.PubMedGoogle Scholar
  42. 42.
    Schell WA. Histopathology of fungal rhinosinusitis. Otolaryngol Clin N Am. 2000;33:251–76.CrossRefGoogle Scholar
  43. 43.
    Corey JR, Delsupeke KG, Ferguson BJ. Allergic fungal sinusitis: allergic, infectious or both? Otolaryngol Head Neck Surg. 1995;113:110–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Washburn RG, Kennedy DW, Begley MG, Henderson DK, Bennett JE. Chronic fungal sinusitis in apparently normal hosts. Medicine (Baltimore). 1988;67:231–47.Google Scholar
  45. 45.
    MacMillan III RH, Cooper PH, Body BA, Mills AS. Allergic fungal sinusitis due to Curvularia lunata. Hum Pathol. 1987;18:960–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Gourley DS, Whisman BA, Jorgensen NL, Martin ME, Reid MJ. Allergic Bipolaris sinusitis: clinical and immunopathologic characteristics. J Allergy Clin Immunol. 1990;85:583–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Schell WA. Unusual fungal pathogens in fungal sinusitis. Otolaryngol Clin North Am. 2000;33:367–73.PubMedCrossRefGoogle Scholar
  48. 48.
    Palaoglu S, Sau A, Yalcinlar Y, Scheithauer BW. Cerebral phaeohyphomycosis. Neurosurgery. 1993;33:894–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Horre R, de Hoog GS. Primary cerebral infections by melanized fungi: a review. In: de Horre GS, editor. Studies in Mycology #43: Ecology and Evolution of Black Yeasts and Their Relatives. Baarn: Centralbureau Voor Schimmel; 1999. p. 176–93.Google Scholar
  50. 50.
    Rohwedder JJ, Simmons JL, Colfer H, Gatmaitan B. Disseminated Curvularia lunata infection in a football player. Arch Intern Med. 1979;139:940–1.PubMedCrossRefGoogle Scholar
  51. 51.
    Flanagan KL, Bryceson AD. Disseminated infection due to Bipolaris australiensis in a young immunocompetent man: case report and review. Clin Infect Dis. 1997;25:311–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Khan JA, Hussain ST, Hasan S. Disseminated Bipolaris infection in an immunocompetent host: an atypical presentation. J Am Med Assoc. 2002;50:68–71.Google Scholar
  53. 53.
    Li DM, de Hoog GS. Cerebral phaeohyphomycosis: at cure at what lengths? Lancet Infect Dis. 2009;9:376–83.PubMedCrossRefGoogle Scholar
  54. 54.
    Marr KA, Carter RA, Crippa RA, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMedCrossRefGoogle Scholar
  55. 55.
    Marco de Lucas E, Sádaba P, Lastra García-Barón P, et al. Cerebral scedosporiosis: an emerging fungal infection in severe neutropenic patients: CT features and CT pathologic correlation. Eur Radiol. 2005;16:496–502.PubMedCrossRefGoogle Scholar
  56. 56.
    Tintelnot K, Wagner N, Seibold M, de Hoog GS, Horré R. Re-identification of clinical isolates of the Pseudallescheria boydii-complex involved in near-drowning. Mycoses. 2008;51 Suppl 3:11–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003;37:221–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Schell WA. New aspects of emerging fungal pathogens. A multifaceted challenge. Clin Lab Med. 1995;15:365–87.PubMedGoogle Scholar
  59. 59.
    Schell WA, Perfect JR. Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol. 1996;34:1333–6.PubMedGoogle Scholar
  60. 60.
    Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45–54.PubMedGoogle Scholar
  61. 61.
    Bennett JE, Bonner H, Jennings AE, Lopez RI. Chronic meningitis caused by Cladosporium trichoides. Am J Clin Pathol. 1973;59:398–407.PubMedGoogle Scholar
  62. 62.
    Kantarcioglu AS, de Hoog GS. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses. 2004;47:4–13.PubMedCrossRefGoogle Scholar
  63. 63.
    Georg LK, Bierer BW, Cooke WB. Encephalitis in turkey poults due to a new fungus species. Sabouraudia. 1964;3:239–44.PubMedGoogle Scholar
  64. 64.
    Sides EH, Benson JD, Padhye AA. Phaeohyphomycotic brain abscess due to Ochroconis gallopavum in a patient with malignant lymphoma of a large cell type. J Med Vet Mycol. 1991;29:317–22.PubMedCrossRefGoogle Scholar
  65. 65.
    Kanj SS, Amr SS, Roberts GD. Ramichloridium mackenziei brain abscess: report of two cases and review of the literature. Med Mycol. 2001;39:97–102.PubMedGoogle Scholar
  66. 66.
    Watanabe S, Hironaga M. An atypical isolate of Scedoporium apiospermum from a purulent meningitis in man. Sabouraudia. 1981;19:209–15.PubMedGoogle Scholar
  67. 67.
    Yoo D, Lee WHS, Kwon-Chung KJ. Brain abscess due to Pseudallescheria boydii associated with primary non-Hodgkin’s lymphoma of the central nervous system: a case report and literature review. Rev Infect Dis. 1985;7:272–7.PubMedGoogle Scholar
  68. 68.
    Dworzack DL, Clark RB, Padgett PJ. New causes of pneumonia, meningitis, and disseminated infections associated with immersion. Infect Control Hosp Epidemiol. 1987;1:615–33.Google Scholar
  69. 69.
    Perfect JR, Durack DT. Pathogenesis and management of fungal infections in the central nervous system. In: Scheld WM, Whitley RJ, Durack DT, editors. Infections of the Central Nervous System. New York: Lippincott-Raven; 1997. p. pp 21–738.Google Scholar
  70. 70.
    Sigler L. Miscellaneous opportunistic fungi: microascaceae and other ascomycetes, hyphomycetes, coelomycetes and basidiomycetes. In: Howard DH, editor. Fungi Pathogenic for Humans and Animals, revised and expanded. 2nd ed. New York: Marcel Dekker; 2003. p. 637–76.Google Scholar
  71. 71.
    Viviani MA, Tortorano AM, Laria G, Giannetti A, Bignotti G. Two new cases of cutaneous alternariosis with a review of the literature. Mycopathologia. 1986;96:3–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Wiest PM, Wiese K, Jacobs MR, et al. Alternaria infection in a patient with acquired immune deficiency syndrome: case report and review of invasive Alternaria infections. Rev Infect Dis. 1987;9:799–803.PubMedGoogle Scholar
  73. 73.
    Pastor FJ, Guarro J. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol Infect. 2008;14:734–46.PubMedCrossRefGoogle Scholar
  74. 74.
    Morrison VA, Weisdorf DJ. Alternaria: a sinonasal pathogen of immunocompressed hosts. Clin Infect Dis. 1993;16:265–70.PubMedGoogle Scholar
  75. 75.
    Rolston KV, Hopfer RL, Larson DL. Infections caused by Drechslera species: case report and review of the literature. Rev Infect Dis. 1985;7:525–9.PubMedGoogle Scholar
  76. 76.
    Adam RD, Paquin ML, Peterson EA. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature. Medicine (Baltimore). 1986;65:203–17.Google Scholar
  77. 77.
    Karim M, Sheikh H, Alam M, Sheikh Y. Disseminated Bipolaris infection in an asthmatic patient: case report. Clin Infect Dis. 1993;17:248–53.PubMedGoogle Scholar
  78. 78.
    Latham RH. Bipolaris spicifera meningitis complicating a neurosurgical procedure. Scand J Infect Dis. 2000;32:102–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Schell WA, Esterre P. Chromoblastomycosis. In: Merz WG, Hay R, editors. Topley and Wilson’s Microbiology and Microbial Infections, Medical Mycology. 10th ed. London: Edward Arnold; 2005. p. 356–66.Google Scholar
  80. 80.
    Monte SMD, Hutchens GM. Disseminated Curvularia infection. Arch Pathol Lab Med. 1985;109:872–4.PubMedGoogle Scholar
  81. 81.
    Yau YC, de Nanassy J, Summerbell RC, Matlow AG, Richardson SE. Fungal sternal wound infection due to Curvularia lunata in a neonate with congenital heart disease: case report and review. Clin Infect Dis. 1994;19:735–40.PubMedGoogle Scholar
  82. 82.
    Fernandez M, Noyola DE, Rosemann SN, Edwards MS. Cutaneous phaeohyphomycosis caused by Curvularia lunataand a review of Curvulariainfections in pediatrics. Pediatr Infect Dis J. 1999;18:727–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Janaki C, Sentamilselvi G, Janaki VR, Devesh S, Ajithados K. Eumycetoma due to Curvularia lunata. Mycoses. 1999;2:345–6.CrossRefGoogle Scholar
  84. 84.
    Carter E, Boudreaux C. Fatal cerebral phaeohyphomycosis due to Curvaularia lunata in an immunocompetent host. J Clin Microbiol. 2004;42:5419–23.PubMedCrossRefGoogle Scholar
  85. 85.
    Tintelnot K, de Hoog GS, Thomas E, Steudel WI, Huebner K, Seeliger HPR. Cerebral phaeohyphomycosis caused by an Exophiala species. Mycoses. 1991;34:239–44.PubMedCrossRefGoogle Scholar
  86. 86.
    Gold WL, Vellend H, Salit IE, Campbell I, Summerbell R, Rinaldi M, et al. Successful treatment of systemic and local infections due to Exophiala species. Clin Infect Dis. 1994;19:339–41.PubMedGoogle Scholar
  87. 87.
    Morris A, Schell WA, McDonagh D, Chafee S, Perfect JR. Fonsecaea pedrosoi pneumonia and Emericella nidulans cerebral abscesses in a bone marrow transplant patient. Clin Infect Dis. 1995;21:1346–8.PubMedGoogle Scholar
  88. 88.
    Najafzadeh MJ, Gueidan C, Badali H, Gerrits van den Ende AHG, Lian X, de Hoog GS. Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Med Mycol. 2009;47:17–25.PubMedCrossRefGoogle Scholar
  89. 89.
    Ndiaye B, Develoux M, Dieng MT, Kane A, Ndir O, Raphenon G, et al. Current report of eumycetoma in Senegal: report of 109 cases. J Mycol Med. 2000;10:140–4.Google Scholar
  90. 90.
    Gilgado F, Cano J, Gene J, Guarro J. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol. 2005;43:4930–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Gilgado F, Cano J, Gene J, Sutton DA, Guarro J. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol. 2008;46:766–71.PubMedCrossRefGoogle Scholar
  92. 92.
    Berenguer J, Diaz-Mediavilla J, Urra D, Munoz P. Central nervous system infection caused by Pseudallescheria boydii: case report and review. Rev Infect Dis. 1989;11:890–6.PubMedGoogle Scholar
  93. 93.
    Berenguer J, Rodriquez-Tudela JL, Richard C. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Medicine (Baltimore). 1997;76:256–65.CrossRefGoogle Scholar
  94. 94.
    Maertens J, Lagrou K, Deweerdt H. Disseminated infection by Scedosporium profilicans: An emerging fatality among haematology patients. Case report and review. Ann Hematol 2001; 79:340-344Google Scholar
  95. 95.
    Hiruma M, Kawada A, Ohata H, Ohnishi Y, Takahashi H, Yamazaki M, et al. Systemic phaeohyphomycosis caused by Exophiala ­dermatitidis. Mycoses. 1993;36:1–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Matsumoto T, Matsuda T, McGinnis MR, Ajello L. Clinical and mycological spectra of Wangiella dermatitidis infection. Mycoses. 1992;36:145–55.CrossRefGoogle Scholar
  97. 97.
    Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.PubMedCrossRefGoogle Scholar
  98. 98.
    Nucci M, Akiti T, Barreiros G, Silveira F, Revankar SG, Sutton DA, et al. Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and Rhinocladiella species newly described causes of bloodstream infection. J Clin Microbiol. 2001;39:514–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Gerrits van den Ende AHG, de Hoog GS. Variability and molecular diagnostics of the neyurotropic species Cladophialophoraa bantiana. Studies in Mycology 43: Ecology and Evolution of Black Yeasts and Their Relatives. Baarn/Delft, The Netherlands: Centralbureau Voor Schimmel. 1999, pp 151–162.Google Scholar
  100. 100.
    Heinz T, Serafin DB, Schell WA, Perfect JR. Soft tissue fungal infections: surgical management of 12 immunocompromised patients. Plast Reconstr Surg. 1996;97:1391–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis. 2004;38:206–16.PubMedCrossRefGoogle Scholar
  102. 102.
    Shimosaka S, Waga S. Cerebral chromoblastomycosis ­complicated by meningitis and multiple fungal aneurysms after resection of a granuloma. Case Report. J Neurosurg. 1983;59:158–61.PubMedCrossRefGoogle Scholar
  103. 103.
    Ferguson BJ. Fungus balls of the paranasal sinuses. Otolaryngol Clin North Am. 2000;33:389–98.PubMedCrossRefGoogle Scholar
  104. 104.
    McGinnis MR, Pasarell RL, Sutton DA. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother. 1997;41:1821–34.Google Scholar
  105. 105.
    Espinel-Ingroff A. In vitro activity of the new triazole voriconazole UK 109, 496 against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998;36:198–202.PubMedGoogle Scholar
  106. 106.
    Espinel-Ingroff A. A comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK 0991 L-743, 872 and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950–6.PubMedGoogle Scholar
  107. 107.
    McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol. 1998;36:243–6.PubMedGoogle Scholar
  108. 108.
    Sharkey PK, Graybill JR, Rinaldi MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol. 1990;23:577–86.PubMedCrossRefGoogle Scholar
  109. 109.
    Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol. 2009;47:41–3.PubMedCrossRefGoogle Scholar
  110. 110.
    Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis. 2003;36:112–1131.CrossRefGoogle Scholar
  111. 111.
    Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop São Paulo. 2005;47:339–46.PubMedGoogle Scholar
  112. 112.
    Negroni R, Helou SH, Petri N, Robles Am, Arechavala A, Bianchi MH. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis. 2004;38:e15–20.PubMedCrossRefGoogle Scholar
  113. 113.
    Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592,­­ ­amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (Ramichloridium mackenziei). Antimicrob Agents Chemother. 2000;44:1159–62.PubMedCrossRefGoogle Scholar
  114. 114.
    Heath Ch, Slavin MA, Sorrell TC, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect. 2009;15:689–93.PubMedCrossRefGoogle Scholar
  115. 115.
    Walsh TJ, Lutsar I, Driscoll T, Dupont B, Rhoden M, Gharamani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–8.PubMedCrossRefGoogle Scholar
  116. 116.
    Troke P, Aquirrebengoak K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedCrossRefGoogle Scholar
  117. 117.
    Rodriques-Tudela JL, Berenguer J, Guarro J, Kantarcioglu AS, Horre R, de Hoog GS, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009;47:359–70.CrossRefGoogle Scholar
  118. 118.
    Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis in patients with acute leukemia; a retrospective multicenter report. Haematologica. 2008;93:104–10.PubMedCrossRefGoogle Scholar
  119. 119.
    Queiroz-Telles F, Esterre P, Perez-Blanco M, Vital RG, Salgado CG, Bonifaz A. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3–15.PubMedCrossRefGoogle Scholar
  120. 120.
    Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743, 872 against a variety of clinically important moulds. Antimicrob Agents Chemother. 1997;41:1835–6.PubMedGoogle Scholar
  121. 121.
    Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20:121–36.PubMedGoogle Scholar
  122. 122.
    Meletiadis J, Mouton JW, Rodriquez-Tudela JL. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000;44:470–2.PubMedCrossRefGoogle Scholar
  123. 123.
    Ferguson BJ. What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? Arch Otolaryngol Head Neck Surg. 1998;124:1174–8.PubMedGoogle Scholar
  124. 124.
    CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved Standard-Second Edition. CLSI document M38-A2. Wayne: Clincal and Laboratory Standards Institute. 2008.Google Scholar
  125. 125.
    Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38 document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:5243–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavagthu E, Ostrosky-Zeichner L, Pfaller M, et al. Quality control and Reference Guidelines for CLSI Broth Microdilution Method (M38-A Document) for Susceptibility Testing of Anidulafungin against Molds. J Clin Microbiol. 2007;45:2180–2.PubMedCrossRefGoogle Scholar
  127. 127.
    Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007;45:1811–20.PubMedCrossRefGoogle Scholar
  128. 128.
    Fuste FJ, Ajello L, Threlkeld R, Henry Jr JE. Drechslera hawaiiensis: causative agent of a fatal fungal meningo-encephalitis. Sabouraudia. 1973;11:59–63.PubMedGoogle Scholar
  129. 129.
    Seaworth BJ, Kwon-Chung CJ, Hamilton JD, Perfect JR. Brain abscess caused by a variety of Cladosporium trichoides. Am J Clin Pathol. 1983;79:747–52.PubMedGoogle Scholar
  130. 130.
    Dixon DM, Walsh TJ, Merz WG, McGinnis MR. Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis. 1989;11:515–25.PubMedGoogle Scholar
  131. 131.
    Sekhon AS, Galbraith J, Mielke BW, Garg AK, Sheehan G. Cerebral phaeohyphomycosis caused by Xylohypha bantiana, with a review of the literature. Eur J Epidemiol. 1992;8:387–90.PubMedCrossRefGoogle Scholar
  132. 132.
    Greer KE, Gross GP, Cooper PH, Harding SA. Cystic chromomycosis due to Wangiella dermatitidis. Arch Dermatol. 1979;115:1433–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • John R. Perfect
    • 1
  • Barbara D. Alexander
  • Wiley A. Schell
  1. 1.Duke Mycology Research Unit, Division of Infectious Diseases and International HealthDuke University Medical CenterDurhamUSA

Personalised recommendations